Eli Lilly to supply U.S. with 300,000 doses of anti-SARS-CoV-2 antibody

By The Science Advisory Board staff writers

October 28, 2020 -- Eli Lilly has entered an initial agreement with the U.S. government to supply 300,000 vials of LY-CoV555 (bamlanivimab), the company's investigational neutralizing antibody to fight SARS-CoV-2 infection, for $375 million.

The U.S. government will accept the doses if the drug is granted an emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). The company submitted a request for an EUA for bamlanivimab for the treatment of mild to moderate COVID-19 in high-risk patients to the FDA in early October.

If the EUA is granted, the government has committed that patients will have no out-of-pocket costs for the medicine. Lilly is partnering with Operation Warp Speed and a national distributor to finalize distribution plans and shipping arrangements.

The initial agreement is for delivery over two months following an EUA and provides the U.S. government with the option to purchase up to an additional 650,000 vials through June 30, 2021.

The company anticipates manufacturing up to 1 million doses of bamlanivimab by the end of 2020 for use around the world. Supply of the therapy is expected to increase substantially beginning in early 2021.

Lilly to supply COVID-19 therapy to low-income nations
Eli Lilly and the Bill & Melinda Gates Foundation have launched an initiative to supply low- and middle-income countries with COVID-19 therapeutic...
Eli Lilly seeks EUA from FDA for its SARS-CoV-2 mAbs
Eli Lilly submitted an emergency use authorization (EUA) request from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 monoclonal antibodies...
Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.
Eli Lilly rolls out early COVID-19 antibody trial data
Eli Lilly released early data from a phase II clinical trial that explored the use of the neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter